Novacyt Publishes Delayed 2025 Annual Report Following Audit
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
novacytannual-report
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Novacyt SA published its annual report and audited financial statements for the year ended December 31, 2025, on June 11, 2026. The release follows a period of delayed reporting pending the completion of an audit by the company’s new auditor, BDO LLP. The filing provides a full account of the company’s financial performance and strategic position after a substantial transition from its COVID-19 related revenue streams. This disclosure is a critical compliance milestone for the London-listed molecular diagnostics company, which had previously released unaudited preliminary results.
The publication of the annual report concludes a period of investor uncertainty regarding Novacyt’s financial governance. The company’s reporting timeline was impacted by the appointment of BDO LLP as its new statutory auditor in 2025, a change that typically necessitates a comprehensive onboarding process. This delay occurred against a backdrop of heightened regulatory scrutiny on financial disclosures globally, particularly for companies that experienced rapid growth during the pandemic. The completion of the audit signals a return to standard reporting cadence, a key factor for institutional investor confidence. For companies like Novacyt, which are navigating a post-pandemic market, transparent and timely financials are essential for accessing capital and maintaining market credibility. The event is a procedural necessity that carries weight for a firm repositioning its core business.
The annual report confirms the preliminary figures announced earlier, detailing a challenging financial year. Group revenue for 2025 was €9.8 million, a significant decline from the pandemic-era peak of over €500 million in 2021. The company reported an operating loss of €25.4 million, reflecting ongoing restructuring costs and R&D investments. Novacyt’s cash and cash equivalents position was reported at €32.5 million as of December 31, 2025. This provides a crucial runway for its strategic shift towards non-COVID-19 product lines in oncology and infectious diseases.
| Metric | 2025 | 2021 (Peak) | Change |
|---|---|---|---|
| Revenue | €9.8M | ~€500M | -98% |
| Operating Profit/(Loss) | (€25.4M) | ~€280M | N/A |
| Cash & Equivalents | €32.5M | N/A | N/A |
The company’s current market capitalization of approximately £40 million contrasts with its cash position, indicating market skepticism about its growth prospects. This valuation is typical for small-cap healthcare stocks in a high-interest-rate environment where profitability is prioritized.
The report’s primary market impact is the removal of a key overhang on the stock (CNYT.L), potentially reducing volatility stemming from disclosure risks. The confirmed cash balance of €32.5 million is analytically positive, as it alleviates immediate liquidity concerns and funds the transition strategy. This may lead to a reassessment by specialist healthcare funds that focus on small-cap life sciences companies with strong balance sheets. Peer companies in the molecular diagnostics space, such as Hologic (HOLX) and Qiagen (QGEN), are insulated from this event due to their scale and diversified revenue. A counter-argument is that the report only confirms known financial weakness and does not alter the fundamental challenge of rebuilding a sustainable revenue base. Trading flow is likely dominated by existing shareholders rebalancing positions rather than new institutional entry, with short interest potentially decreasing post-filing.
The immediate catalyst for Novacyt is its interim report for the first half of 2026, expected by the end of September 2026. Investors will scrutinize this for early signs of commercial traction from new product launches in its Primerdesign and Lab21 products divisions. Key levels to watch for the stock include the tangible net asset value, largely supported by its cash holdings, which could act as a support floor. Further strategic updates on partnerships or acquisitions, funded by the existing cash reserve, are potential market-moving events through the second half of the year. The company’s ability to achieve its stated goal of breaking even on an EBITDA basis by the end of 2026 remains the critical metric for long-term valuation.
The delay was primarily due to the transition to a new auditor, BDO LLP. Appointing a new auditor requires a full audit cycle, including planning, substantive testing, and final review, which extended the timeline beyond the standard reporting date. This is a common occurrence during auditor changes, especially for companies with complex international operations and a history of significant transactions, as seen with Novacyt during the pandemic.
Novacyt is pivoting its business towards a portfolio of non-COVID molecular diagnostics tests. The strategy focuses on leveraging its existing technology platform for areas like oncology, infectious diseases, and genetic testing. This involves both internal research and development and potential acquisitions or partnerships, using its cash reserves to build a more diversified and sustainable revenue stream less dependent on a single pathogen.
An auditor change can create short-term uncertainty, often leading to increased stock volatility until the new auditor affirms the company's financials. While sometimes routine, it can signal internal disagreements or heightened scrutiny. The resolution, marked by the publication of an audited report, typically reduces this uncertainty and is viewed positively, as it confirms the company’s financial controls and reporting integrity under the new oversight.
Novacyt’s belated 2025 report confirms a difficult transition but provides a clear cash-backed runway for its new strategy.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.